OptiBiotix Health PLC Marketing update (9473D)
February 25 2020 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 9473D
OptiBiotix Health PLC
25 February 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Marketing update
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, provides the following marketing
update.
SlimBiome(R) is Generally Recognized as Safe ("GRAS")
OptiBiotix has self-affirmed its patented SlimBiome(R)
ingredient is GRAS per US Code 21 CFR 170.30. This affirmation is
based on a complete evaluation of all ingredients and processes
used to manufacture SlimBiome(R) and confirmation of GRAS status
for all materials used in the SlimBiome(R) formulation. GRAS status
is a United States Food and Drug Administration (FDA) requirement
for any ingredient or additive used in food products sold in the
United States.
Online Subscription Service
OptiBiotix has introduced a subscription service for its on line
store www.optibiotix.online. The service allows customers to
subscribe to repeat orders and benefit from a discount on product
and delivery costs. Currently the first order is 10% off, with
subsequent orders thereafter at a 15% discount to help encourage
continual subscription. The subscription service has been
introduced to improve customer convenience and help OptiBiotix
determine future demand allowing better inventory management, and
support ongoing supplier discussions to reduce the cost of goods
and improve margins.
Investor discount code INVESTOR20
OptiBiotix appreciates the ongoing support and feedback from its
investors on existing and new products. This helps the Company
improve existing products (e.g. a new smaller CholBiomeX3 tablet),
and feeds directly into its new product development pipeline. It
plans to launch a range of new products with retail partners, and
on its online store in the coming months. These include a range of
healthy snacks (e.g fruit and fibre gummies) under the
SnackSmart(TM) brand, pancake mixes, a new blueberry and raspberry
snack bar, and an extension of its breakfast range to include
porridge containing SlimBiome(R).
In recognition of the valuable feedback OptiBiotix receives from
its investors, and to broaden investor engagement in the
development of new products and the success of OptiBiotix, the
Company has created a new discount code, INVESTOR20. This gives
investors 20% off the list price of the online product when
spending over GBP45. The code cannot be used with other discount
codes but can be used with the subscription service. This means
that investors who subscribe and use the INVESTOR20 code can get
30% off all products (10% for subscribing and 20% off with the
investor code). The code is valid for one month which may be
extended or new codes offered to support product launches.
Stephen O'Hara, CEO of OptiBiotix, commented: "OptiBiotix is
pleased to update investors on a number of developments which
support the commercialisation of its ingredients and products. Self
affirming SlimBiome(R) as GRAS will support commercialisation of
SlimBiome(R) as a food ingredient in the $7.6bn (2020, Statistica)
food and beverage market in the USA. The subscription service and
investor discount code is designed to improve customer convenience,
improve inventory management, and support the development and
launch of a range of new products on www.optibiotix.online and with
retail partners in future months."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than 20 international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASELFILESSEEE
(END) Dow Jones Newswires
February 25, 2020 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024